A Movement in Muscle
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel oral small-molecule therapies for serious skeletal and cardiac muscle diseases including Duchenne muscular dystrophy, Becker muscular dystrophy, and hypertrophic cardiomyopathy. Founded in 2017 and headquartered in Boulder, Colorado, the company uses its proprietary muscle biology platform to identify and advance muscle-selective drug candidates with the goal of improving function and quality of life for patients with rare muscle disorders.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountApr 2025
Jan 2024
Mar 2021
Dec 2020
Sep 2019
Create a free account to see which investors have funded this company.
Create Free Account
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
Clinical-stage biopharmaceutical developing precision medicines targeting novel mechanisms to tre...
Denali Therapeutics is a biotechnology company focused on discovering and developing treatments f...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
